PARP3抗体

+ +

•  

   

     Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane: Human cerebrum tissue lysate, Primary antibody: P05138(PARP3 Antibody) at dilution 1/200, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 1 minute    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human gastric cancer tissue using P05138(PARP3 Antibody) at dilution 1/20. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human ovarian cancer tissue using P05138(PARP3 Antibody) at dilution 1/20. (Original magnification: ×200)    

  
  

Poly(ADP-ribose) polymerase 3 (PARP3) is a member of the PARP enzyme family, which plays roles in DNA repair, genomic stability, and cellular stress responses. Unlike its well-characterized relatives PARP1 and PARP2. PARP3 exhibits distinct functional properties. It lacks the automodification domain critical for PARP1’s hyperactivation and shows preferential involvement in the repair of DNA double-strand breaks via non-homologous end joining (NHEJ). PARP3 also participates in mitotic progression, centromere integrity, and adaptation to oxidative stress, making it a multifaceted regulator of genome maintenance.

PARP3 antibodies are essential tools for studying its expression, localization, and molecular interactions. They enable detection of endogenous PARP3 in techniques like Western blotting, immunofluorescence, and immunoprecipitation. These antibodies are particularly valuable in cancer research, as PARP3 dysregulation has been linked to tumorigenesis, chemoresistance, and sensitivity to PARP inhibitors. Validated antibodies often target conserved regions, such as the catalytic domain or unique N-terminal motifs, to ensure specificity given the high homology among PARP family members. Challenges include distinguishing PARP3 from other PARPs due to structural similarities and low basal expression levels in some tissues. Recent studies using PARP3-knockout models or siRNA have improved antibody validation, clarifying its role in DNA damage responses and potential therapeutic targeting. Reliable PARP3 antibodies thus underpin advancing research into its biological mechanisms and clinical relevance.